Friendship Biotech-B (02496.HK): Two clinical research data for the "CD3/EpCAM bispecific antibody" will be presented at the 2026 ASCO Annual Meeting.

Wisdom Finance News App, YuZhiYuSheng Biology-B (02496.HK) announced that the two clinical research results of the company's core national class 1 innovative drug M701 "CD3/EpCAM bispecific antibody" will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting: phase III registration clinical study for malignant ascites (MA), phase II clinical study for malignant pleural effusion (MPE) related to non-small cell lung cancer (NSCLC).